Overall , the posttrial group had fewer adverse events ( 18 % vs 34 % , P = .02 ) , specifically fewer wound infections ( 2 % vs 14 % , P = .001 ) and fewer unplanned readmissions ( 7 % vs 16 % , P = .04 ) than the pretrial group .